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Abstract
Worldwide osteoarthritis (OA) affects more than 9.6% of men and
18% of women older that 60 years. Treatment for OA often
requires chronic use of selective or nonselective nonsteroidal anti-
inflammatory drugs (NSAIDs), which have been associated with
gastrointestinal and cardiovascular complications. An increased
risk for upper gastrointestinal bleeding with NSAIDs alone and when
combined with low-dose aspirin has been described in numerous
studies. Although cyclo-oxygenase-2 inhibitors have been shown
to carry a lower risk for gastrointestinal injury than nonselective
NSAIDs, research continues to identify new treatments that not
only are effective but also provide an improved benefit/risk profile,
including better gastrointestinal tolerability. Nitric oxide (NO) is
known to have a protective effect on the gastrointestinal tract. In
preclinical studies NO was shown to help maintain gastric mucosal
integrity, to inhibit leukocyte adherence to the endothelium, and to
repair NSAID-induced damage. In addition, epidemiologic studies
have shown that the use of NO-donating agents with NSAIDs or
aspirin resulted in reduced risk for gastrointestinal bleeding.
Recent studies have shown that cyclo-oxygenase inhibiting NO-
donating drugs (CINODs), in which a NO molecule is chemically
linked to an NSAID, are effective anti-inflammatory agents and may
result in less gastrointestinal damage than is associated with NSAID
use. Therefore, these agents provide a potential therapeutic option
for patients with arthritis who require long-term NSAID therapy.
Introduction
Osteoarthritis (OA) is an increasingly prevalent disease and
results in pain and disability in affected individuals. Current
treatments include nonsteroidal anti-inflammatory drugs
(NSAIDs) to reduce pain and inflammation. However, both
cardiovascular and gastrointestinal risks are associated with
NSAID therapy that can limit their use to treat chronic pain
[1,2]. In the gastrointestinal tract, use of NSAIDs disrupts
gastroprotective mechanisms, including mucus secretion
and blood flow [3]. This results in adverse events, including
mucosal ulceration and, eventually, abdominal discomfort
and gastrointestinal bleeding, or more rarely perforation
[1,2,4,5].
The search for new agents with which to manage pain and to
reduce the attendant adverse events associated with NSAID
use has led to the development of a new class of agents
termed cyclo-oxygenase (COX)-inhibiting, nitric oxide (NO)-
donating drugs (CINODs). CINODs are NO donors in which
NO is coupled to an NSAID and could potentially improve the
gastrointestinal safety profile of traditional NSAIDs [6,7]. This
review discusses the known functions of NO in the gastro-
intestinal tract and some of the mechanisms that underlie
NSAID-induced gastric damage. The potential benefits of
NO-donating agents in the treatment of NSAID-induced
gastric damage are reviewed, and finally the potential benefits
of CINODs in the management of OA are discussed.
Nitric oxide synthesis and nitric oxide
synthase enzymes
NO mediates multiple physiological functions in the gastro-
intestinal tract, including mucosal blood flow, maintenance of
mucosal integrity, and maintenance of vascular tone. NO is
synthesized by the conversion of L-arginine to equimolar
amounts of L-citrulline and NO. Once NO is generated, it
binds to the heme group of soluble guanylyl cyclase, which
catalyzes the conversion of GTP to cGMP, leading to an
intracellular increase in cGMP concentration [8]. cGMP then
binds to and modifies the target domain of specific proteins,
including protein kinases, ion channels, and phospho-
diesterases, to elicit cellular responses. However, NO can
also act in a cGMP-independent manner, in which redox
derivatives of NO mediate cellular activities by post-
translational modifications or oxidation of proteins and/or
lipids. NO works in the gastrointestinal tract to help maintain
homeostasis and, when disrupted, can perpetuate pathologic
conditions.
The oxidation of L-arginine to L-citrulline and NO is catalyzed
by one of three isoforms of nitric oxide synthase (NOS)
Review
Role of nitric oxide in the gastrointestinal tract
Angel Lanas
Servicio de Aparato Digestivo, Hospital Clinico Zaragoza, CIBERehd, IACS, Universidad de Zaragoza, C/ Domingo Miral s/n, 50009 Zaragoza, Spain
Corresponding author: Angel Lanas, angel.lanas@gmail.com
Published: 17 October 2008 Arthritis Research & Therapy 2008, 10(Suppl 2):S4 (doi:10.1186/ar2465)
This article is online at http://arthritis-research.com/supplements/10/S2/S4
© 2008 BioMed Central Ltd
CINOD = cyclo-oxygenase inhibiting nitric oxide donating; COX = cyclo-oxygenase; eNOS = endothelial nitric oxide synthase; iNOS = inducible
nitric oxide synthase; L-NAME = NG-nitro-L-arginine methyl ester; L-NMMA = NG-monomethyl-L-arginine; NO = nitric oxide; NOS = nitric oxide syn-
thase; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; PPI = proton pump inhibitor; SNAP = S-nitroso-N-acetylpenicillamine;
UGIB = upper gastrointestinal bleeding.Page 2 of 6
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 10 Suppl 2 Lanas
enzymes. At the gastrointestinal level, the two constitutively
expressed isoforms, namely endothelial NOS (eNOS) and
neuronal NOS (nNOS), are expressed basally at the vascular
endothelium and the enteric nervous system of the
gastrointestinal tract, respectively [9]. The inducible isoform
of NOS (iNOS) is expressed in macrophages and
neutrophils, but with potent signals for induction it may also
be observed in epithelial cells and neurons [10]. iNOS is a
calcium-independent enzyme that is upregulated in response
to inflammation and other stimuli, remains activated for longer
periods of time compared with the other isoforms, and
generates a sustained increase in NO [11]. A study of iNOS
expression patterns in the neonatal and adolescent rat
intestine revealed that iNOS activation in response to
lipopolysaccharide-stimulation in the ileum varies with age
[12]. Once iNOS is upregulated, the concentration of NO will
increase, resulting in the production of reactive oxygen
species and ultimately oxidative stress. NO itself, as well as
ROS molecules such as superoxide and peroxynitrite (which
results from the interaction between NO and superoxide
anion) will all act to elicit downstream effects. The effects of
NO reacting with other radicals can induce either deleterious
or even beneficial consequences, depending on the
conditions under which the process takes place [10].
Nitric oxide in the gastrointestinal tract
It is well known that COX-derived prostaglandins play
multiple roles in maintaining the integrity of the gastro-
intestinal mucosa, including stimulation of mucus and
bicarbonate secretion, resistance of epithelial cells to injury,
inhibition of recruitment of leukocytes to the mucosa, and
downregulating the release of inflammatory mediators [13]. It
is now also clear that NO plays a key role in the maintenance
of the gastrointestinal mucosa and that both NO and COX
derived prostaglandins share similarities in various
gastrointestinal functions. NO and prostaglandin mediated
mechanisms of mucosal defense also exhibit a degree of
cooperation. Suppression of one arm can lead to a
compensatory elevation in the other [10,12,14].
NO is responsible for helping to maintain the integrity of the
gastric epithelium and the mucus barrier. NO is a vasodilator
and mediates gastric blood flow. Experiments in rats revealed
that the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA)
induced a dose-dependent increase in systemic blood pressure
and a decrease in resting gastric mucosal blood flow [15].
There is evidence that the addition of exogenous NO, similar
to that provided by a transdermal patch of nitroglycerin in
humans, can help to protect the rat gastric mucosa from
indomethacin-induced gastric damage, perhaps because the
nitroglycerin patch maintains adequate mucosal blood flow
and inhibits leukocyte-endothelial cell interactions [16].
Mucus contributes to gastrointestinal defense by acting as a
physical barrier to damage as well as helping to protect the
epithelium from damage caused by acid and pepsin [10,17].
Brown and coworkers [18] demonstrated that incubation with
NO stimulates mucus secretion in rat gastric mucosal cells in
a dose-dependent manner and that this stimulation is
dependent on cGMP. In vivo experiments [19] subsequently
showed that administration of the NO donor isosorbide
dinitrate to rat gastric lumen leads to a dose-dependent
increase in mucus gel thickness, again demonstrating that
under certain conditions NO helps to mediate mucus secre-
tion to protect the gastric epithelium.
More recent studies have demonstrated that NO also protects
the gastrointestinal tract by inhibiting gastric acid secretion.
Intragastric application of NO donors, including FK409 and
sodium nitroprusside, significantly decreased both basal
secretion and secretion that was stimulated by pentagastrin
and YM-14673, an analog of thyrotropin-releasing hormone
[17]. In addition, incubation with NG-nitro-L-arginine methyl
ester (L-NAME), a NOS inhibitor, enhanced pentagastrin and
YM-14673 stimulated acid secretion but not basal secretion
[20]. These experiments demonstrated that NO helps to
decrease acid secretion from gastric parietal cells.
Subsequent experiments demonstrated that when isolated
human gastric gland cells were incubated with the NO donor
S-nitroso-N-acetylpenicillamine (SNAP), stimulation with
histamine resulted in decreased acid secretion when
compared with controls [21]. Because acid secretion in the
presence of a cGMP analog was inhibited and the presence
of SNAP and a GC synthase inhibitor did not result in a
decrease in gastric acid secretion, the authors concluded
that the role of NO in gastric acid secretion is cGMP-
dependent.
Although prostaglandins and NO are required for normal
gastrointestinal function, there is also some evidence that a
large excess of these compounds may have deleterious
effects on the gastrointestinal tract. COX-2, the inducible
isoenzyme of COX, is induced in the presence of
gastrointestinal mucosal inflammation. Although it has been
reported that COX-2 derived prostaglandins (and probably
NO derived from iNOS as well) are involved in gastric ulcer
repair [22], they also contribute to perpetuation of gastro-
intestinal inflammation [23,24]. In the same way, induction of
NOS may be associated with pathologic conditions. In the
gastrointestinal tract, iNOS is activated in gastritis induced by
Helicobacter pylori infection, inflammatory bowel diseases,
and NSAID-induced ulcerogenesis [10,25,26]. The role
played by and the effect of the excess of NO in these
conditions is unclear. In some experiments, exogenous
addition of NO protected against or reduced the severity of
indomethacin-induced gastric damage in rats [16]. In
contrast, when indomethacin was administered to iNOS
knockout mice there was a reduction in the amount of gastric
damage compared with that in wild-type animals [27]. This
suggests that in this setting, NO generated from iNOS is
involved in indomethacin-induced gastric lesions in thePage 3 of 6
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stomach. These apparently contradictory results illustrate the
difficulty in elucidating the role played by NO in many func-
tions, including NSAID-induced gastric damage. There are
contradictory reports in which low levels of NO are seen to
provide gastroprotection against NSAID-induced ulcerogenic
damage [16,28], whereas higher concentrations lead to
NSAID-induced damage [29,30]; this is similar to what has
been suggested in various experimental models of colitis [10].
Effects of nitric oxide donors on
NSAID-induced damage to the
gastrointestinal tract
The mechanisms that underlie the ulcerogenic properties of
NSAIDs are still being elucidated, but inhibition of mucosal
prostaglandins is a key factor [13,14,17]. Various experi-
mental models have shown that, in addition to the topical
effect of NSAIDs and the COX dependent inhibition of
prostaglandins, other important mechanisms are involved.
Among these, we can highlight a decrease in mucosal blood
flow and induction of leukocyte adherence within the
gastrointestinal mucosal microcirculation as being two
mechanisms of NSAIDs in which NO has a direct effect
[10,13,14,17]. As commented on above, exogenous NO
reduces gastric damage from NSAIDs in rats [16]. Other
experiments also suggest that NO plays a role in reducing
leukocyte adherence within the gastric microcirculation in the
presence of indomethacin [10]. When rats were pretreated
with the NO donor sildenafil, there was a significant reduction
in indomethacin-induced gastric damage compared with
untreated control animals, and this reduction was blocked by
treatment with the NOS inhibitor L-NAME. Furthermore,
leukocyte adhesion was significantly decreased in these
animals, once again suggesting that NO-dependent mecha-
nisms play a role in protection against NSAID-induced
damage [31]. These examples help to define the gastro-
protective effects of NO and suggest that NO donors could
help to protect against NSAID-induced gastric damage.
The toxicity induced by NSAIDs in the intestine has some
specific features. Unlike the stomach and the duodenal bulb,
gastric acid is not present but the intestinal lumen contains
bile and enterobacteria that potentiate the damage after the
initial increase in gut permeability induced by NSAIDs [32].
The inflammatory response that follows these events is
associated with induction of iNOS and increased NO
production in the gut [33-35]. Although the precise effect of
iNOS induction in these experimental settings remains
unclear and excess NO may perpetuate damage, it has been
shown that both NO derived from the different isoforms and
prostaglandins are required to heal and protect intestinal
lesions from NSAIDs [36,37].
Evidence generated from experiments and epidemiologic
studies in humans suggest that exogenous NO has a
protective effect on the gastrointestinal tract, specifically
against NSAID-induced gastric damage. Figure 1 depicts
potential targets for the protective effects of NO against
NSAID-associated pathogenesis [38].
Dietary nitrate
Experimental evidence has demonstrated that dietary nitrate
can help protect against NSAID-induced gastric mucosal
damage. Rats fed nitrate daily in their drinking water exhibited
an increase in the thickness of gastric mucus and an up-
regulation of MUC6, which is a component of mucus in the
gastric mucosa [39]. In addition, nitrate pretreatment reduced
diclofenac-induced gastric lesions in a dose-dependent
manner. Finally, inflammatory activity was decreased in
nitrate-pretreated rats, as indicated by lower mucosal
myeloperoxidase activity and a decrease in iNOS expression.
In a similar study, Petersson and colleagues [40] demon-
strated that rats pretreated with nitrate or given luminal nitrite
had higher gastric mucosal blood flow than did untreated
animals, again suggesting a gastroprotective role for NO.
Because nitrite administered luminally in eNOS-null mice also
resulted in increased gastric blood flow, the authors
suggested that the gastroprotective effects of nitrate were
likely the result of nonenzymatic NO production.
Epidemiologic studies
Epidemiologic studies have illustrated that treatment with
nitrates can reduce the risk for upper gastrointestinal bleed-
ing (UGIB) in patients taking NSAIDs. A case-control study
was conducted to determine the risk for UGIB among
patients taking low-dose aspirin, other NSAIDs, or nitro-
vasodilators (organic nitrates or nitroglycerin) was performed
[41]. After adjustment for age, sex, and clinical risk factors
(including a history of UGIB, a history of ulcer, and the
presence of cardiovascular or cerebrovascular disease), the
use of NSAIDs other than low-dose aspirin and use of low-
Available online http://arthritis-research.com/supplements/10/S2/S4
Figure 1
Potential targets for the gastroprotective effects of NO on NSAID-
induced gastric damage. COX, cyclo-oxygenase; NO, nitric oxide;
NSAID, nonsteroidal anti-inflammatory drug. Data from Mannick and
coworkers [26].dose aspirin were both associated with increased risk for
UGIB. However, the use of nitrovasodilators or antisecretory
therapy, including H2 receptor antagonists and proton pump
inhibitors (PPIs), was associated with a decreased risk for
UGIB, and this decrease was also observed when patients
were receiving NSAID or aspirin therapy.
A more recent, larger case-control study [42], conducted after
the withdrawal from the market of the COX-2 inhibitors
rofecoxib and valdecoxib, confirmed these results. It once again
illustrated that co-therapy with nitrates, PPIs, and H2 receptor
antagonists all decreased the risk for UGIB associated with
NSAID or aspirin use, although the protection conferred by
nitrates was weaker than that by PPIs (Figure 2) [42].
Intriguingly, a specific polymorphism in the eNOS gene that is
associated with an increase in plasma NO concentrations was
found to be associated with decreased risk for UGIB in low-
dose aspirin users [43], again suggesting that additional NO
helps to prevent damage or promote the healing of NSAID-
induced damage to the gastroduodenal mucosa.
CINODs protect against NSAID-induced gastrointestinal
damage
As commented on above, NO has the capacity to block or
compensate for the reduction in mucosal blood flow and can
block the adherence of neutrophils to the vascular endo-
thelium associated with NSAIDs in the gastrointestinal tract.
Based on these properties, it was proposed that linkage of a
NO-releasing moiety to an NSAID could reduce the
gastrointestinal toxicity of these agents [6,7,10,14]. Seminal
experiments in rats showed that NO-releasing derivatives of
NSAIDs (including NO-flurbiprofen, NO-ketoprofen, NO-diclo-
fenac, and NO-naproxen) can spare the gastrointestinal tract
and be as effective as their parent drugs [6,7,10,14,44,45].
NO-naproxen (naproxcinod) administered twice daily for
18 days resulted in significantly less gastric damage than did
naproxen alone. In addition, naproxcinod also had improved
analgesic and comparable anti-inflammatory activities when
compared with naproxen [46]. Comparisons of flurbiprofen
and NO-flurbiprofen showed that blood flow in the duodenum
and mucus accumulation both decreased in the flurbiprofen
treated animals compared with the NO-flurbiprofen groups
[47]. Mucosal permeability also increased in the flurbiprofen
but not NO-flurbiprofen treated animals. These findings
suggest that the positive effects of NO-flurbiprofen may be
due to its ability to maintain gastric blood flow, which may
contribute to the reduced risk for NSAID-induced lesion.
Finally, rats injected subcutaneously with indomethacin or
NO-indomethacin (NCX 530) were analyzed after 24 hours
[48]. Macroscopic observation revealed that indomethacin
exposure led to gastrointestinal damage, primarily in the
jejunum and ileum, along with increased inflammatory activity,
as indicated by myeloperoxidase and iNOS activities. In
addition, indomethacin injections decreased mucus and fluid
secretions. In contrast, NCX-350 injections resulted in no
gross gastric damage and decreased mucosal prostaglandin
E2 content and inflammatory activity.
Some early clinical studies have also been conducted to test
the effects of CINODs in humans. Naproxcinod was adminis-
tered to 31 healthy individuals, and gastrointestinal injury was
compared with that in participants who received naproxen or
placebo [49]. Naproxcinod resulted in fewer gastroduodenal
erosions in both the stomach and duodenum than did
naproxen or placebo. In addition, naproxen alone increased
intestinal permeability whereas naproxcinod and the placebo
did not, suggesting that naproxcinod has an improved
gastrointestinal profile compared with naproxen.
In another study [50], 970 patients were randomly assigned
to receive naproxcinod 750 mg twice daily, naproxen 500 mg
twice daily, or placebo twice daily in a double-blind study.
Compared with baseline, significantly fewer ulcers and
erosions developed in stomach and stomach/duodenum
combined on naproxcinod than on naproxen. The incidence of
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Figure 2
Risks for peptic ulcer bleeding. Presented are adjusted relative risks and 95% confidence intervals for peptic ulcer bleeding associated with the
use of nitrates and gastroprotective agents in the population using NSAIDs or aspirin. ASA, aspirin; H2-RA, H2-receptor antagonist; CI, confidence
interval; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor. Data from Lanas and colleagues [42].ulcers (the primary end-point of the study) was 9.7% with
naproxcinod versus 13.7% (P = 0.07, not significant) with
naproxen and 0% for placebo (Figure 3). The incidence of
Lanza scores >2 was higher with naproxen (43.7%) than
with naproxcinod (32.2%). Naproxcinod was as effective as
naproxen at improving WOMAC (Western Ontario and
McMaster Osteoarthritis Index) scores [50].
Similarly, NO-aspirin (NCX 4016) or aspirin was administered
to healthy individuals, and the anti-inflammatory and anti-
thrombotic effects as well as gastrointestinal tolerability were
compared [51]. The study demonstrated that both NCX 4016
and aspirin had similar effects on platelet aggregation and
inhibition of COX activity. However, NCX 4016 resulted in
significantly less gastric damage than did aspirin alone, as
indicated by endoscopy. In addition, unlike aspirin alone,
NCX 4016 inhibited tissue factor expression on lipopoly-
saccharide-stimulated monocytes, suggesting that NCX 4016
has NO mediated activity in addition to COX inhibiting activity
[51]. These studies confirm results from animal models and in
vitro experiments, and suggest that CINODs could be new
options in the treatment of OA pain that potentially have an
improved gastrointestinal safety profile.
Conclusion
NO has been extensively studied and has well defined
protective functions in the gastrointestinal tract, but when it is
overproduced - as in the case of iNOS activation - the results
can be pathogenic. Nevertheless, epidemiologic and
laboratory experiments demonstrate that exogenous NO can
either prevent or reduce the gastrointestinal toxicity
associated with NSAIDs. Early research with CINODs
supports the hypothesis that exogenous NO helps to protect
against NSAID-induced gastric damage and/or promotes
gastric healing. Although more research is needed, CINODs
appear to be effective anti-inflammatory therapeutic agents
with a potentially improved gastrointestinal safety profile
compared with NSAIDs.
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